✦ LIBER ✦

Pharmacokinetics and Tolerability of the Orally Active Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 in Healthy Volunteers

✍ Scribed by Ms Helen Swaisland, Alison Laight, Lesley Stafford, Helen Jones, Charles Morris, Aaron Dane, Roger Yates

Book ID: 119926344
Publisher: Springer International Publishing AG
Year: 2001
Tongue: English
Weight: 202 KB
Volume: 40
Category: Article
ISSN: 0312-5963
DOI: 10.2165/00003088-200140040-00005

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pharmacokinetics of single and multiple

Pharmacokinetics of single and multiple oral doses of zd 1839 (‘Iressa’), a specific epidermal growth factor receptor tyrosine kinase inhibitor (egfr-tki), in healthy male volunteers

✍ H.C. Swaisland; R. Smith; H. Jones; J. Farebrother; A. Laight 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 184 KB

ChemInform Abstract: Studies Leading to

ChemInform Abstract: Studies Leading to the Identification of ZD1839 (Iressa): An Orally Active, Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Targeted to the Treatment of Cancer.

✍ Keith H. Gibson; et al. et al. 📂 Article 📅 2010 🏛 John Wiley and Sons ⚖ 29 KB 👁 2 views

ZD1839 (‘Iressa’), an orally-active, sel

ZD1839 (‘Iressa’), an orally-active, selective, epidermal growth factor receptor tyrosine kinase inhibitor (egfr-tki), is well tolerated in combination with gemcitabine and cisplatin, in patients with advanced solid tumours: preliminary tolerability, efficacy and pharmacokinetic results

✍ G. Giaccone; J.L. Gonzales-Larriba; E.F. Smit; A.T. van Oosterom; M. Martins; G. 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 338 KB

484 Biological markers associated with s

484 Biological markers associated with sensitivity of tumour cells to the epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 and ionizing radiation

✍ S. Burdak-Rothkamm; C.E. Ruebe; T.P. Nguyen; D. Ludwig; K. Feldmann; T. Wiegel; 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 169 KB

Antitumor activity of the selective epid

Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Iressa® (ZD1839) in an EGFR-expressing multidrug-resistant cell line in vitro and in vivo

✍ Ichiro Naruse; Tohru Ohmori; Yoko Ao; Hisao Fukumoto; Toshio Kuroki; Masatomo Mo 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 French ⚖ 216 KB 👁 1 views

## Abstract Selective tyrosine kinase inhibitors are regarded as promising antitumor agents for cancer treatment. Iressa® (ZD1839) is an orally active, selective EGFR‐TKI (epidermal growth factor receptor‐tyrosine kinase inhibitor) that blocks signal transduction pathways implicated in cancer cell

829 The epidermal growth factor receptor

829 The epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (‘iressa’, ZD-1839) and the protein prenyltransferase inhibitor M365408 as potential therapeutics in bladder cancer

✍ J.L. Dominguez-Escrig; J. Kelly; B.R. Davies 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 192 KB